Androgens and mesenchymal factors are essential extracellular signals for the development
as well as the functional activity of the prostate epithelium. Little is known of the …

In many patients with prostate cancer, the cancer will be recurrent and eventually progress
to lethal metastatic disease after primary treatment, such as surgery or radiation therapy. …

Patients with advanced prostate cancer almost invariably develop osseous metastasis.
Although many studies indicate that the activation of NF-κB signaling appears to be correlated …

Androgen receptor splicing variants (ARVs) that lack the ligand-binding domain (LBD) are
associated with the development of castration-resistant prostate cancer (CRPC), including …

Identification of factors that mediate visceral and bone metastatic spread and subsequent
bone remodeling events is highly relevant to successful therapeutic intervention in advanced …

Sterol regulatory element-binding protein 1 (SREBP-1), a master transcription factor in
lipogenesis and lipid metabolism, is critical for disease progression and associated with poor …

Typically, the initial response of a prostate cancer patient to androgen ablation therapy is
regression of the disease. However, the tumor will progress to an “androgen-independent” …

When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated
the Prostate Steering Committee 15 years ago, there were no genetically engineered …

Castration-resistant prostate cancer can be treated with the antiandrogen enzalutamide, but
responses and duration of response are variable. To identify genes that support …

Background The development of benign prostatic hyperplasia (BPH) and medication‐refractory
lower urinary tract symptoms (LUTS) remain poorly understood. This study attempted to …